After the stock of Alder BioPharmaceuticals fell off a cliff, plummeting to just over $12 on Thursday from its $55 peak two years ago, Jim Cramer had to find out what went wrong. The decline was only accelerated on Wednesday when the small-capitalization company announced a huge secondary offering and the stock lost almost 20 percent of its value....